Rakovina Therapeutics’ Post

🚀 Dive into the future of drug discovery! Join us this Wednesday, February 28, for a live discussion on #Xspaces. 🤖🧬 @Rakovina_RKV in collaboration with Follow the Money Investor Group Discover the transformative power of AI in the drug discovery process with insights from industry leaders 👇 Jeffrey Bacha, our Executive Chairman Mads Daugaard, our President & Chief Scientific Officer and Artem Cherkasov, the newest member of our Scientific Advisory Board Don't miss out on this dynamic conversation shaping the future of oncology. See you there! 👩🔬👨💼 #AI #DrugDiscovery #Innovation #biotech

We are excited to announce that CHARM Therapeutics has been showcased by CB Insights as one of the 100 most promising private AI companies of 2024. The 100 winners were chosen based on several factors, including CB Insights’ data on deal activity, industry partnerships, team strength, investor strength, patent activity, and their proprietary Mosaic Scores, which is created by cross-referencing thousands of datapoints to predict a company’s success. CHARM Therapeutics stands out among these top AI companies due to our unique DragonFold platform. This end-to-end 3D deep learning protein-ligand co-folding technology is designed for the discovery and development of small molecule therapeutics enabling CHARM to target and develop treatments for previously hard-to-drug targets in cancer and other therapeutic areas. To read the full AI 100 list: https://lnkd.in/gJENamuX #deeplearning #AI

I believe we’re at a pivotal moment in how clinical trials are approached. With the advances in computational technology and the vast data we’ve accumulated, there’s no excuse not to do better. The potential to improve trial success rates and accelerate life-saving treatments has never been greater. 🙌 Ready to take on the challenge and make a difference? Join us and be part of the change! Read the Manifesto  👉 https://lnkd.in/da6nW36v #CAST #Biotech #Innovation #CancerResearch #ClinicalTrials

Welcome Andrew Lo to the n-Lorem Board of Directors. His expertise in creating novel economic models that provide solutions for cost of care for rare illnesses could open the door for more nano-rare patients to receive treatment. Andrew is a co-founder of BridgeBio Pharma, QLS Advisors, Quantile Health, and Uncommon Cures; a director of AbCellera, Atomwise, BridgeBio, Uncommon Cures, and Vesalius; and a member of the advisory board to the American Cancer Society’s BrightEdge Impact Fund. His healthcare-related research interests include: new financial engineering tools and business models for drug and device development and healthcare delivery, especially for rare and ultra-rare diseases; statistical methods for incorporating patient preferences into the drug approval process; predicting clinical trial outcomes via machine learning techniques; and novel reimbursement models for creating a robust gene and cell therapy ecosystem. https://lnkd.in/gMSvtV-H

Hype vs. Reality: The #AI Revolution in #drugdiscovery - I think we are still in the very early days.. UK-based Exscientia and its AI-designed cancer drug, EXS-21546, alongside similar endeavors by BenevolentAI and Recursion, faced clinical hurdles. the market didn't respond well; stocks have plummeted, reflecting investor skepticism. We have to remind ourselves that R&D success in #pharma is very limited and these are only handful of early experiments. Companies like Generate:Biomedicines, Verge Genomics, BPGbio Inc., Insilico Medicine, Auransa and Nimbus Therapeutics continue to push the envelope in integrating #AI. We need to remind ourselves about Moderna's covid success. This is a journey demanding patience, perseverance, and a nuanced understanding of both technology's capabilities and limitations.

🚀 Revolutionizing Drug Discovery with AI 💊 The world of drug discovery is witnessing an unprecedented transformation, thanks to artificial intelligence (AI)! 🤖 By sifting through and analyzing massive volumes of data, AI is unlocking valuable insights that can pave the way for groundbreaking medical treatments. 🧪 Among the most promising AI tools are deep-learning models like generative adversarial networks (GANs) and Autoencoders. These cutting-edge technologies are not only expediting the creation of new drugs but also enhancing their quality and effectiveness. 📈 As the benefits of AI become increasingly apparent, we're seeing a surge in collaborations between AI and pharmaceutical companies. Together, they're committed to developing drug candidates in a swift, efficient, and cost-effective manner, ultimately revolutionizing the way we approach healthcare. 🌟 Source in comment Take a look at our discussion with Dr. Violet Zahedi, cofounder at Synamics Therapeutics working on this game-changing intersection of AI and medicine! 💡 👉https://lnkd.in/eHg5AH4M #AIinHealthcare #DrugDiscovery #Innovation #MedTech #cancer #oncology #drugdesign

T-1 day until DDIF 2024 GBX EVENTS kicks off! Excited to dive into groundbreaking presentations from industry leaders on innovations in digital transformation, GenAI, AI-driven drug discovery, and more. Key topics: - GenAI's role in healthcare and pharma - Transforming cancer and age-related treatments with AI and cell therapy - Patient-first drug discovery - The impact of quantum computing Looking forward to the fireside chats and hearing insights from CxOs about their journey and vision for the future. Exciting times for healthcare ahead!

Streamline your clinical data operations with MaxisIT Inc.'s AI-Powered Data Management Workbench (DMW). Our case study with a leading Oncology biotech company highlights significant time savings and enhanced efficiency. Swipe through the carousel to see how DMW’s automation is transforming data management, freeing up valuable resources, and significantly enhancing overall clinical trials effectiveness. Explore more here: https://lnkd.in/eUF78Kpi #ClinicalTrials #ClinicalResearch #ClinicalDataManagement #AI #Oncology #Biotech #MaxisIT

✨ ✨ ✨ I'd like to kick off a new series highlighting some of the best and brightest across the Life Science space ✨ ✨ ✨   My first instalment of this kicks off with a company doing incredible work in the Drug Design space... 🥁 🥁   Exscientia   🔎 They utilise precision information derived from patient tissues alongside sophisticated AI technology to source optimised drug profiles for research. This integrated system has been the first to demonstrate improved clinical outcomes in oncology, and I believe that is just the beginning in their revolution.   📈 They currently have four targets at pre clinical, and phase 1-2, across Haematology, Oncology, and Inflammatory Diseases. With 40% of total clinical growth within Biotech/ Pharmaceuticals sitting within Oncology in 2023, Exscientia should be on your radar!   🗞 With the recent appointment of Marie-Louise Fjaellskog, and promotion of John Overington, I can't wait to see the continued success of this truly pioneer company. #Biotech #innovation #AI #DrugDesign

We are pleased to announce that we have raised $16M in seed funding. The investment will enable the advancement of our AI cell simulation platform for identifying safe rejuvenation genes — a key step in developing therapeutics for age-related diseases. Led by BGF, with participation from F-Prime Capital, Kindred Capital VC, and Jonathan Milner Meltwind Advisory LLP, this round brings our total funding to $18M, positioning us to tackle the growing burden of age-related illnesses. Read the full press release https://lnkd.in/ek_Bz9zS Aging is the largest driver of disease. At Shift Bioscience, we are building a cell simulation platform that combines generative AI with a highly accurate, high-throughput biological aging clock to predict, test, and validate gene sets that can safely rejuvenate specific cells, with the aim of designing more effective drugs to treat age-related diseases. https://lnkd.in/eXiGV5-s #AI #rejuvenation #Aging #AgeRelatedTherapies